Abstracts
Showing 851 abstracts.
Citation
Brookie M. Best, Pharm.D., Edmund Capparelli, Pharm.D., Alice M. Stek, M.D., Sandra K. Burchett, M.D., M.S., Jennifer S. Read, M.D., M.P.H., M.S., DTM&H, Elizabeth (Betsy) Smith, M.D., ChengCheng Hu, Ph.D., Jennifer L. Gardella, M.P.H., Carol Elgie, B.S., Joanne E. Schiffhauer, B.S., Mark Mirochnick, M.D. Abacavir Phamacokinetics in Pregnancy.Study
P1026S
Citation
Mary D. Boland, R.N., M.S.N, D.P.H., Deborah S. Storm, R.N.,Ph.D, Steven Gortmaker, Ph.D., James M. Oleske, M.D. Antiretroviral therapy and quality of life in children with perinatally acquired HIV infection.Citation
Caroline J. Chantry, M.D., Joseph S. Cervia, M.D., F.A.C.P., F.A.A.P., Janice Hodge, R.N., B.S., Michael Hughes, Ph.D., John ( Jack ) Moye, Jr., M.D. Body Compostion and Biochemical Changes in Children Starting of Switiching Combination Antiretroviral Chemotherapy.Study
P1010
Citation
John H. Rodman, Pharm.D., Ram Yogev, M.D., Elaine J. Abrams, M.D., Stephen Ira Pelton, M.D., Pearl Samson, M.S., Terence Fenton, Ed.D., Ellen Gould Chadwick, M.D. Pharmacokinetics of Indinavir (IDV) at Two Dose Levels of Ritonavir (RTV) for HIV-infected Children Failing Antiretroviral Therapy.Study
P1013
Citation
Kumud K. Singh, Akihiko Saitoh, M.D., Christine Powell, M.A., Terence Fenton, Ed.D., Courtney V. Fletcher, Pharm.D., Richard Brundage, Pharm.D., Ph.D., Stuart E. Starr, M.D., Stephen A. Spector, M.D. Allelic Variants of MDRI Alter Pharmacokinetics of Nelfinavir Resulting in Higher Drug Levels and More Rapid Decline in Plasma HIV-1 RNA in Children.Citation
Heather D. Watts, M.D., Rajalaksh Balasubramanian, Sc.D., Robert T. Maupin, Jr., M.D., Issac Delke, M.D., Coleen K. Cunningham, M.D., Alejandro Dorenbaum, M.D., Simone Fiore, M.D., Marie Louise Newell, M.D., Jean-Francois Delfraissy, M.D., Richard D. Gelber, Ph.D., Lynne M. Mofenson, M.D., F.A.A.P., Mary Culnane, C.R.N.P., M.S., John L. Sullivan, M.D. Maternal Toxicity and Pregnancy Outcome According to Antiretroviral Therapy during Pregnancy. An analysis of the PACTG 316 Study.Citation
Wayne M. Dankner, M.D., Sharon Appelbaum Nachman, M.D., Michael Hughes, Ph.D., Philimon Gona, Ph.D., Sharon Huang, M.S., Sharon Huang, M.S., Carol Elgie, B.S., Ram Yogev, M.D. An Observational Study of the Rate of Opportunistic Infection (OI) Events In HIV-Infected Children Who Have Demonstrated Immunologic Reconstitution And Who Have Discontinued OI Prophylaxis.Study
P1008
Citation
Pearl Samson, M.S., Richard M. Rutstein, M.D., Steven M. Schnittman, M.D., Alberto A. Ortiz, M.S., Bobbie L. Graham, B.S., Terence Fenton, Ed.D., Grace M. Aldrovandi, MD. Effects of Antiretroviral Exposure and Genotypic Mutations in Predicting Phenotypic Resistance to Atazanavir (ATV), Lopinavir (LPV), and Tenofovir (TDF) in Patients Naive to these Drugs. Presented at: 13th Symposium on HIV and Emerging Infectious Diseases; 2004 Jun 14.Conference
13th Symposium on HIV and Emerging Infectious Diseases
Study
P1020A
Citation
Lois C. Howland, M.S., M.P.H., D.Ph., Deborah S. Storm, R.N.,Ph.D, Sybil Crawford, Ph.D., James M. Oleske, M.D. Change in prevalence of stressful life events and sociodemographic factors in children with HIV infection between 1993 and 2000. Presented at: Eastern Nursing Research Society 2004.Conference
Eastern Nursing Research Society 2004